WebOct 3, 2024 · In a recent report of investigation conducted in a pediatric HLH cohort, 12 patients with newly diagnosed secondary HLH were treated with ruxolitinib as the first-line treatment, and 10 patients (83%) showed improvement at 28 days with no significant adverse effects . However, the use of ruxolitinib in patients with AIDS remains rare. WebMar 23, 2024 · This interplay is of clinical significance due to its association with hemophagocytic lymphohistiocytosis (HLH) and/or EBV-driven malignancies. Here, we report a case of SMBA that developed in a 14-year-old Hispanic boy that led to fatal secondary HLH.
A study of ruxolitinib response-based stratified treatment …
WebJun 16, 2024 · Ruxolitinib had low toxicity and was well tolerated compared with intensive chemotherapy. Our study provides clinical evidence for ruxolitinib as a frontline agent for … WebSep 1, 2024 · Discussion. HLH is a potentially fatal syndrome, with mortality rates reaching up to 50% in pediatric patients even with protocolized treatment [10].In adult patients, mortality rates have been reported to exceed 40% [1].Of note, treatment recommendations from the HLH-94 and HLH-2004 protocols have been adopted in the adult population, but … first ponies for sale
Pediatric hemophagocytic lymphohistiocytosis: A rarely …
WebHLH-2004 are largely extrapolated from pediatric HLH; however, the prognosis of adult HLH is worse than that of children.1,2 In addition to its unsatisfactory efficacy, the toxicity of HLH-94/HLH-2004 regi- ... Ruxolitinib has been reported to have a risk of hematologi-cal toxicity, which is difficult to evaluate because cytopenia is also the WebSubgroup analysis, however showed a reduced mortality in ruxolitinib-treated patients with a high fever. This trial also showed that ruxolitinib therapy exhibited a better safety profile … WebJun 1, 2024 · Ruxolitinib had low toxicity and was well tolerated compared with intensive chemotherapy. Our study provides clinical evidence for ruxolitinib as a frontline agent for pediatric HLH. The efficacy was particularly exemplified with stratified regimens based on the early differential response to ruxolitinib. first political scientist